Cargando…
Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial
BACKGROUND: The 2013 GOLD classification system for COPD distinguishes four stages: A (low symptoms, low exacerbation risk), B (high symptoms, low risk), C (low symptoms, high risk) and D (high symptoms, high risk). Assessment of risk is based on exacerbation history and airflow obstruction, whateve...
Autores principales: | Goossens, Lucas M A, Leimer, Inge, Metzdorf, Norbert, Becker, Karin, Rutten-van Mölken, Maureen PM H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223746/ https://www.ncbi.nlm.nih.gov/pubmed/25326750 http://dx.doi.org/10.1186/1471-2466-14-163 |
Ejemplares similares
-
Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial
por: Tashkin, Donald P, et al.
Publicado: (2015) -
Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT(®) Trial
por: Halpin, David M. G., et al.
Publicado: (2011) -
Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022) -
Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018) -
Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial
por: Celli, Bartolomé R., et al.
Publicado: (2016)